Neuroprotective effects of memantine via enhancement of autophagy

Kazuoki Hirano, Motoki Fujimaki, Yukiko Sasazawa, Akihiro Yamaguchi, Kei Ichi Ishikawa, Kengo Miyamoto, Sanae Souma, Norihiko Furuya, Yoko Imamichi, Daisuke Yamada, Hideyuki Saya, Wado Akamatsu, Shinji Saiki, Nobutaka Hattori

研究成果: Article

抄録

Introduction: Chemical intervention of autophagy has been investigated in clinical trials for various age-related conditions such as sarcopenia and neurodegeneration. However, at present, no autophagy inducer has been established as a disease-modifying agent against neurodegenerative diseases. Methods: We screened a library consisting of 796 medicines clinically approved (in Japan) for autophagy enhancers as potential neurodegeneration therapeutics using HeLa cells stably expressing green fluorescent protein-microtubule-associated protein light chain 3 (GFP-LC3) followed by an analysis of the molecular mechanisms using various neuronal models. Results: The primary screening identified 152 hits in a static cellular state. A widely available Alzheimer's disease drug, memantine, which antagonizes N-Methyl-D-aspartate receptor (NMDAR), was one of the hits. Memantine increased the levels of LC3-II in a dose-dependent and time-dependent manner, and upregulated autophagic flux. In addition, the pharmacological effects of memantine on autophagy were independent of mTORC1 activity and NMDAR activation. Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Notably, intracellular Huntington's disease-specific aggregates of elongated huntingtin, a well-established autophagy substrate, were significantly decreased by memantine. In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Conclusion: These findings indicate that memantine may be beneficial for the treatment of neurodegeneration characterized by the abnormal accumulation of autophagy or mitophagy substrates.

元の言語English
ページ(範囲)161-170
ページ数10
ジャーナルBiochemical and Biophysical Research Communications
518
発行部数1
DOI
出版物ステータスPublished - 2019 10 8

Fingerprint

Memantine
Autophagy
Neuroprotective Agents
Mitochondrial Degradation
N-Methyl-D-Aspartate Receptors
Neurodegenerative diseases
Sarcopenia
Induced Pluripotent Stem Cells
Mitochondria
Microtubule-Associated Proteins
Huntington Disease
Substrates
Green Fluorescent Proteins
Stem cells
HeLa Cells
Neurodegenerative Diseases
Libraries
Neurons
Medicine
Japan

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

これを引用

Hirano, K., Fujimaki, M., Sasazawa, Y., Yamaguchi, A., Ishikawa, K. I., Miyamoto, K., ... Hattori, N. (2019). Neuroprotective effects of memantine via enhancement of autophagy. Biochemical and Biophysical Research Communications, 518(1), 161-170. https://doi.org/10.1016/j.bbrc.2019.08.025

Neuroprotective effects of memantine via enhancement of autophagy. / Hirano, Kazuoki; Fujimaki, Motoki; Sasazawa, Yukiko; Yamaguchi, Akihiro; Ishikawa, Kei Ichi; Miyamoto, Kengo; Souma, Sanae; Furuya, Norihiko; Imamichi, Yoko; Yamada, Daisuke; Saya, Hideyuki; Akamatsu, Wado; Saiki, Shinji; Hattori, Nobutaka.

:: Biochemical and Biophysical Research Communications, 巻 518, 番号 1, 08.10.2019, p. 161-170.

研究成果: Article

Hirano, K, Fujimaki, M, Sasazawa, Y, Yamaguchi, A, Ishikawa, KI, Miyamoto, K, Souma, S, Furuya, N, Imamichi, Y, Yamada, D, Saya, H, Akamatsu, W, Saiki, S & Hattori, N 2019, 'Neuroprotective effects of memantine via enhancement of autophagy', Biochemical and Biophysical Research Communications, 巻. 518, 番号 1, pp. 161-170. https://doi.org/10.1016/j.bbrc.2019.08.025
Hirano K, Fujimaki M, Sasazawa Y, Yamaguchi A, Ishikawa KI, Miyamoto K その他. Neuroprotective effects of memantine via enhancement of autophagy. Biochemical and Biophysical Research Communications. 2019 10 8;518(1):161-170. https://doi.org/10.1016/j.bbrc.2019.08.025
Hirano, Kazuoki ; Fujimaki, Motoki ; Sasazawa, Yukiko ; Yamaguchi, Akihiro ; Ishikawa, Kei Ichi ; Miyamoto, Kengo ; Souma, Sanae ; Furuya, Norihiko ; Imamichi, Yoko ; Yamada, Daisuke ; Saya, Hideyuki ; Akamatsu, Wado ; Saiki, Shinji ; Hattori, Nobutaka. / Neuroprotective effects of memantine via enhancement of autophagy. :: Biochemical and Biophysical Research Communications. 2019 ; 巻 518, 番号 1. pp. 161-170.
@article{8480e4b55ed84d86a0ead2433a7a6a8f,
title = "Neuroprotective effects of memantine via enhancement of autophagy",
abstract = "Introduction: Chemical intervention of autophagy has been investigated in clinical trials for various age-related conditions such as sarcopenia and neurodegeneration. However, at present, no autophagy inducer has been established as a disease-modifying agent against neurodegenerative diseases. Methods: We screened a library consisting of 796 medicines clinically approved (in Japan) for autophagy enhancers as potential neurodegeneration therapeutics using HeLa cells stably expressing green fluorescent protein-microtubule-associated protein light chain 3 (GFP-LC3) followed by an analysis of the molecular mechanisms using various neuronal models. Results: The primary screening identified 152 hits in a static cellular state. A widely available Alzheimer's disease drug, memantine, which antagonizes N-Methyl-D-aspartate receptor (NMDAR), was one of the hits. Memantine increased the levels of LC3-II in a dose-dependent and time-dependent manner, and upregulated autophagic flux. In addition, the pharmacological effects of memantine on autophagy were independent of mTORC1 activity and NMDAR activation. Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Notably, intracellular Huntington's disease-specific aggregates of elongated huntingtin, a well-established autophagy substrate, were significantly decreased by memantine. In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Conclusion: These findings indicate that memantine may be beneficial for the treatment of neurodegeneration characterized by the abnormal accumulation of autophagy or mitophagy substrates.",
keywords = "Autophagy, Chemical screening, Memantine, Mitophagy, Neurodegenerative diseases",
author = "Kazuoki Hirano and Motoki Fujimaki and Yukiko Sasazawa and Akihiro Yamaguchi and Ishikawa, {Kei Ichi} and Kengo Miyamoto and Sanae Souma and Norihiko Furuya and Yoko Imamichi and Daisuke Yamada and Hideyuki Saya and Wado Akamatsu and Shinji Saiki and Nobutaka Hattori",
year = "2019",
month = "10",
day = "8",
doi = "10.1016/j.bbrc.2019.08.025",
language = "English",
volume = "518",
pages = "161--170",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Neuroprotective effects of memantine via enhancement of autophagy

AU - Hirano, Kazuoki

AU - Fujimaki, Motoki

AU - Sasazawa, Yukiko

AU - Yamaguchi, Akihiro

AU - Ishikawa, Kei Ichi

AU - Miyamoto, Kengo

AU - Souma, Sanae

AU - Furuya, Norihiko

AU - Imamichi, Yoko

AU - Yamada, Daisuke

AU - Saya, Hideyuki

AU - Akamatsu, Wado

AU - Saiki, Shinji

AU - Hattori, Nobutaka

PY - 2019/10/8

Y1 - 2019/10/8

N2 - Introduction: Chemical intervention of autophagy has been investigated in clinical trials for various age-related conditions such as sarcopenia and neurodegeneration. However, at present, no autophagy inducer has been established as a disease-modifying agent against neurodegenerative diseases. Methods: We screened a library consisting of 796 medicines clinically approved (in Japan) for autophagy enhancers as potential neurodegeneration therapeutics using HeLa cells stably expressing green fluorescent protein-microtubule-associated protein light chain 3 (GFP-LC3) followed by an analysis of the molecular mechanisms using various neuronal models. Results: The primary screening identified 152 hits in a static cellular state. A widely available Alzheimer's disease drug, memantine, which antagonizes N-Methyl-D-aspartate receptor (NMDAR), was one of the hits. Memantine increased the levels of LC3-II in a dose-dependent and time-dependent manner, and upregulated autophagic flux. In addition, the pharmacological effects of memantine on autophagy were independent of mTORC1 activity and NMDAR activation. Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Notably, intracellular Huntington's disease-specific aggregates of elongated huntingtin, a well-established autophagy substrate, were significantly decreased by memantine. In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Conclusion: These findings indicate that memantine may be beneficial for the treatment of neurodegeneration characterized by the abnormal accumulation of autophagy or mitophagy substrates.

AB - Introduction: Chemical intervention of autophagy has been investigated in clinical trials for various age-related conditions such as sarcopenia and neurodegeneration. However, at present, no autophagy inducer has been established as a disease-modifying agent against neurodegenerative diseases. Methods: We screened a library consisting of 796 medicines clinically approved (in Japan) for autophagy enhancers as potential neurodegeneration therapeutics using HeLa cells stably expressing green fluorescent protein-microtubule-associated protein light chain 3 (GFP-LC3) followed by an analysis of the molecular mechanisms using various neuronal models. Results: The primary screening identified 152 hits in a static cellular state. A widely available Alzheimer's disease drug, memantine, which antagonizes N-Methyl-D-aspartate receptor (NMDAR), was one of the hits. Memantine increased the levels of LC3-II in a dose-dependent and time-dependent manner, and upregulated autophagic flux. In addition, the pharmacological effects of memantine on autophagy were independent of mTORC1 activity and NMDAR activation. Furthermore, a VPS34 inhibitor suppressed the memantine-induced LC3-II upregulation, suggesting that memantine may affect VPS34 complex activity. Notably, intracellular Huntington's disease-specific aggregates of elongated huntingtin, a well-established autophagy substrate, were significantly decreased by memantine. In addition, memantine enhanced elimination of degraded mitochondrial in neurons derived from induced pluripotent stem cells of PARK2 or PARK6 patients, who exhibited defective PINK1/parkin-mediated mitophagy, suggests that memantine accelerated the clearance of damaged mitochondria. Conclusion: These findings indicate that memantine may be beneficial for the treatment of neurodegeneration characterized by the abnormal accumulation of autophagy or mitophagy substrates.

KW - Autophagy

KW - Chemical screening

KW - Memantine

KW - Mitophagy

KW - Neurodegenerative diseases

UR - http://www.scopus.com/inward/record.url?scp=85070720182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070720182&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2019.08.025

DO - 10.1016/j.bbrc.2019.08.025

M3 - Article

C2 - 31431260

AN - SCOPUS:85070720182

VL - 518

SP - 161

EP - 170

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -